Top Markets
#1 Wiki Cat Wiki Cat +27.83%
#2 Ribbita by Virtuals Ribbita by Virtuals +19.03%
#3 PulseChain PulseChain +16.92%
#4 Bitway Bitway +16.87%
#5 Velvet Velvet +16.62%
#6 Cysic Cysic +15.53%
#7 TRIA TRIA +15.19%
#8 Siren Siren +14.04%
#9 Wrapped Bitcoin (PulseChain) Wrapped Bitcoin (PulseChain) +13.76%
#10 KUB Coin KUB Coin +13.60%
Coin of the day
Wiki Cat Wiki Cat
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Inhibitor Therapeutics, Inc. Inhibitor Therapeutics, Inc.

Inhibitor Therapeutics, Inc.

INTI
Classement en actions #30838
Inhibitor Therapeutics, Inc., established in 1992 and based in Tampa, Florida,... Inhibitor Therapeutics, Inc., established in 1992 and based in Tampa, Florida, is a pharmaceutical development enterprise. The company is dedicated to inventing and commercializing medical treatments for patients in the United States who suffer from various cancerous and non-cancerous cell proliferation conditions. A primary focus of their work involves advancing SUBA-Itraconazole, an oral variant of the drug itraconazole, for therapeutic applications in prostate and lung cancers. Furthermore, Inhibitor Therapeutics, Inc. has successfully completed a positive Phase 2b clinical trial for SUBA-Itraconazole in the management of basal cell carcinoma nevus syndrome. The organization was previously known as HedgePath Pharmaceuticals, Inc. until its name was officially changed in August 2019.
Prix de l'action
$0.089
Dernière synchronisation: 2026-08-17
Capitalisation boursière
$15.36M
Changement (1 jour)
50.59%
Changement (1 an)
111.85%
Pays
US
Échange Inhibitor Therapeutics, Inc. (INTI)

Catégorie

Healthcare
Bénéfices pour Inhibitor Therapeutics, Inc. (INTI)
Bénéfices en 2026 TTM : 0
Selon les derniers rapports financiers de Inhibitor Therapeutics, Inc., les bénéfices actuels de l'entreprise sont de 0. En 2026, l'entreprise a réalisé un bénéfice de 0, égal à celui de 2026 qui était de 0. Les bénéfices affichés sur cette page correspondent aux bénéfices avant intérêts et impôts, appelés aussi EBIT.
Historique des bénéfices pour Inhibitor Therapeutics, Inc. de 2026 à 2026
Bénéfices à la fin de chaque année
Année Bénéfices Changez
Pas assez de données pour les dates fournies.
Bénéfices des entreprises similaires ou concurrentes
Entreprise Bénéfices Différence de bénéfices Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
$1.61B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE